



**Global Media Contacts:**

Christine Lydon  
+44-20-7395-7145

[christine.lydon@fleishmaneuropa.com](mailto:christine.lydon@fleishmaneuropa.com)

Iva Ng  
OrbusNeich  
+852 3109-7268

[ing@orbusneich.com](mailto:ing@orbusneich.com)

**OrbusNeich's COMBO™ Dual Therapy Stent to be featured at EuroPCR 2015**  
*Vessel healing discussed at one of Europe's largest cardiology congresses*

**Hong Kong [12 May, 2015]** OrbusNeich, a global company specializing in the provision of life-changing vascular solutions, will host a symposium featuring the COMBO Dual Therapy Stent at the forthcoming EuroPCR 2015 conference which takes place in Paris, France, from 19th to 22nd May.

The symposium, entitled '*Does true vessel healing matter?*' will take place from 12:30pm CEST-1:30pm CEST on Thursday 21st May, in room 241 of the Palais Des Congrès de Paris in Paris, France. The event will be chaired by Dr Michael Haude, Professor and Director of Medical Clinic, Städtische Kliniken, Neuss Lukaskrankenhaus, and co-chaired Dr Renu Virmani, President and Medical Director, CV Path Institute, United States.

The session will also feature Dr Roxana Mehran, M.D., Director of Interventional Cardiovascular Research and Clinical Trials, Mount Sinai Medical Center, United States, Dr Robbert J. de Winter, MD, AMC, The Netherlands and Dr Michael Joner, M.D., CEO, CVPath Institute, United States.

"The COMBO Stent delivers excellent early healing benefits and stability over the long-term by rapidly healing the vessel," said Dr Michael Haude. "Its EPC technology represents a significant advancement in the field of interventional cardiology. The symposium will give delegates a greater insight into this technology, while providing insights into the correlation of tissue coverage and vessel healing under advanced imaging technology."

## Agenda:

- Session objectives – Dr Renu Virmani
- Correlation of tissue coverage and true vessel healing under OCT imaging - Dr Michael Joner
- Discussion and audience interaction
- Long term validation of the dual therapy stent for everyday use – Dr Roxana Mehran
- Discussion and audience interaction
- Where does COMBO stand in the DAPT controversy? – Dr Robbert J. De Winter
- Discussion and audience interaction
- Session evaluation and key learnings – Dr Michael Haude

EuroPCR is the official congress of the EAPCI (European Association of Percutaneous Cardiovascular Interventions) which is held annually in Paris, which brings cardiologists from around the world together to discuss and to learn about the latest advances in cardiovascular disease.

### **COMBO Dual Therapy Stent - Repair, Regenerate, Naturally**

COMBO is the world's first and only dual therapy stent designed to repair vessel injury and regenerate endothelium, fostering natural, true vessel healing. It does this by accelerating endothelial coverage and controlling neo-intimal proliferation. This is done through a combination of the proven EPC capturing technology and a sirolimus drug elution, delivered from a bioresorbable polymer that is completely degraded within 90 days.

OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

### **About OrbusNeich – Pioneers in life-changing technologies**

OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, R Stent™, Scoreflex™, Sapphire™ II, Sapphire™ II Pro, Sapphire™ NC and Sapphire™ II NC. OrbusNeich is headquartered in Hong Kong and has

operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit [www.OrbusNeich.com](http://www.OrbusNeich.com).

Learn more about our life-changing technologies on our social media channels:

Twitter: [www.twitter.com/OrbusNeich](http://www.twitter.com/OrbusNeich)

LinkedIn: [www.linkedin.com/company/orbusneich-medical](http://www.linkedin.com/company/orbusneich-medical)

YouTube: <http://www.youtube.com/user/OrbusNeichMedia>

###